Nektar Therapeutics
NKTR
Market cap $167M

0.9078 USD

+0.0073

0.81%

At close Dec 24, 4:00 PM EST

After hours

0.8928

-0.0150

1.65%

1 day

0.81%

5 days

-11.00%

1 month

-16.72%

3 months

-24.98%

6 months

-22.41%

Year to date

52.62%

1 year

74.58%

5 years

-95.93%

10 years

-93.96%

About: Nektar Therapeutics is a pharmaceutical company focused on the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. The company is focused on discovering and developing medicines in the field of immunotherapy. Its clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases (e.g. rezpegaldesleukin and NKTR-0165, respectively) and cancer (e.g. NKTR-255).

Employees: 137

Healthcare Pharmaceutical Preparations

Funds holding %

of 6,809 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

691% more call options, than puts

Call options by funds: $182K | Put options by funds: $23K

28% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 18

4% more funds holding

Funds holding: 134 [Q2] → 139 (+5) [Q3]

6% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 35

5% more capital invested

Capital invested by funds: $175M [Q2] → $183M (+$8.07M) [Q3]

0.01% more ownership

Funds ownership: 76.62% [Q2] → 76.64% (+0.01%) [Q3]

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

341%

upside

Avg. target

$5.50

506%

upside

High target

671%

upside

2 analyst ratings

2 positive

100%

0 neutral

0 negative

Piper Sandler Yasmeen Rahimi 48% 1-year accuracy 14 / 29 met price target	671%upside $7	Overweight Initiated	4 Nov 2024
BTIG Robert Hazlett 0% 1-year accuracy 0 / 3 met price target	341%upside $4	Buy Assumed	30 Sept 2024

See Analyst Rankings

Financial journalist opinion

Neutral

PRNewsWire

2 weeks ago

Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting

73% of the NKTR-255 treatment group compared to 50% of the placebo group achieved a complete response at 6 months NKTR-255 enhanced CAR T-cell kinetics with improved CD8+ CAR-T area under the curve (AUC) 0-15 days post-administration being 5.8-fold greater than placebo-controls SAN FRANCISCO , Dec. 7, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced results of its Phase 2 proof-of-concept study evaluating NKTR-255 as an adjuvant treatment to enhance complete response rate (CRR) and durability following CD19-directed CAR-T therapy in patients with relapsed/refractory (R/R) Large B-cell Lymphoma (LBCL) at the 66th ASH Annual Meeting and Exposition in San Diego, California. NKTR-255 is an investigational polymer-conjugated IL-15 agonist, that activates, proliferates and expands natural killer (NK) and CD8+ T-cells in vivo, as well as promotes the survival and expansion of memory CD8+ T cells intended to increase duration and level of response for CAR-T and cellular therapies.1,2 In this multicenter, double-blind Phase 2 study, patients were randomized to receive one of three dose regimens of NKTR-255 or placebo intravenously starting 14 days after CAR-T infusion.

$Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting$